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Potent anti-tumor T cell response and efficient intratumoral T cell infiltration
are the major challenges for therapeutic cancer vaccines. To address these
issues, a nanovaccine system is designed to promote anti-tumor T cell
responses, and intratumoral infiltration is examined in various murine tumor
models. Subcutaneous vaccination with nanodiscs carrying human
papillomavirus (HPV)-16 E7 antigen elicits as high as ∼32% E7-specific
CD8𝜶+ T cell responses in circulation, representing a 29-fold improvement
over the soluble peptide vaccination. Importantly, nanodisc vaccination also
promotes robust intratumoral T cell infiltration and eliminates HPV16
E6/E7-expressing TC-1 tumors at mucosal sites, including lungs, inner lip,
and intravaginal tissues. In a benchmark study with a live Listeria vaccine
combined with anti-PD-1 IgG, nanodiscs plus anti-PD-1 immune checkpoint
blockade elicits comparable levels of T cell responses with anti-tumor efficacy.
Furthermore, compared with Complete Freund’s Adjuvant combined with
tetanus toxoid, nanodisc vaccination in HLA-A02 mice generates >200-fold
stronger IFN-𝜸+ T cell responses against a neoantigen from an HLA-A02
melanoma patient. Overall, these results show that the nanodisc system is a
promising cancer vaccine platform for inducing anti-tumor T cell responses.
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1. Introduction
Induction of anti-tumor T cell responses
with vaccination is an attractive therapeutic
strategy against multiple types of cancer,[1-4]
and various cancer vaccine platforms have
been reported to induce tumor-specific T
cell responses.[5-12] Cancer vaccines can
be generally classified into 2 categories:
live vector-based vaccines[6,9,10] and subunit
vaccines.[7,11,12] The inherent pathogen-like
properties of live vectors allow for the in-
duction of strong innate and adaptive im-
mune responses.[10,13] For example, several
clinical trials have examined TA-HPV,[9] a
live recombinant vaccine virus-based hu-
man papillomavirus (HPV) vaccine encod-
ing E6 and E7 antigen of HPV 16 and 18
as well as Lm-LLO-E7,[6,10] a live attenu-
ated Listeriamonocytogenes vector express-
ing E7 and listeriolysin O. Despite their
ability to induce cytotoxic T lymphocyte
(CTL) responses in humans,[4,6,9,14,15] live
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Figure 1. Schematic illustration of nanodisc vaccination and immune monitoring in HPV16 mucosal tumor models.
vector-based vaccines need to overcome many challenges.[4,16]
First, their therapeutic effects are hindered by pre-existing immu-
nity against the vector itself as well as neutralizing anti-vector an-
tibodies generated after multiple immunizations.[4,16,17] Second,
safety concerns and adverse effects associated with live vectors
pose additional challenges.[4] For instance, 40% of patients expe-
rienced severe grade 3 side effects in a phase I clinical trial with
Lm-LLO-E7.[6]
On the other hand, subunit vaccines, composed of defined
tumor antigens and immunostimulatory agents, offer safer
alternatives.[5,7,12] However, weak T cell responses and inefficient
intratumoral infiltration of T cells are the major hurdles to
overcome.[4] Here, we sought to address these issues with a
potent subunit vaccine platform based on nanodiscs. “Blank”
nanodiscs, composed of phospholipids and Apolipoprotein-
mimetic peptide, have been previously manufactured in Kg
scales and shown to be safe in humans for cardiovascular
applications, thus providing a promising platform for drug
delivery applications.[18] We have reported that nanodiscs carry-
ing peptide antigens and adjuvant molecules efficiently deliver
them to dendritic cells (DCs) in lymph nodes (LNs), leading to
strong anti-tumor T cell responses in combination with immune
checkpoint blockade (ICB).[5,19,20] Therefore, nanodiscs with
demonstrated large scale manufacturability, safety, and potency
for immune activation offer an attractive platform for cancer
vaccination.
Using the nanodisc technology, here we aimed to answer the
following questions: 1)What is the optimal route of nanodisc vac-
cination for promoting antigen-specific T cell responses and T
cell infiltration into the tumormicroenvironment (TME)? 2)How
does the therapeutic efficacy of nanodiscs compare with other
leading vaccine technologies, such as live Listeria vaccine? 3) Can
we demonstrate the wide applicability of nanodisc technology
with clinically relevant human HLA-restricted antigens? To ad-
dress these questions, we have compared the subcutaneous (s.c.)
versus the intranasal (i.n.) route of nanodisc vaccination using
HPV16 E7 antigen and assessed their anti-tumor efficacy in mul-
tiple mucosal tumor models (Figure 1). Although prophylactic
vaccines have been highly effective against HPV infection,[21-23]
development of successful therapeutic vaccines against estab-
lished HPV+ cancer,[4,11,24,25] such as in head & neck and cervical
cancer,[21,22,26,27] has been elusive due to inefficient T cell induc-
tion and infiltration into mucosal TME.[28]
Here, using TC-1 cells expressing HPV16 E6/E7 oncoprotein,
we have demonstrated that s.c. nanodisc vaccination in mice
induced as high as ≈32% E7-specific CD8+ T cell response
among all CD8+ T cells in circulation, promoting robust T cell
infiltration into peripheral mucosal tissues. In TC-1 models of
HPV-associated lung metastasis, head and neck,[29] and cervi-
cal cancer,[27,30] we show that s.c. nanodisc vaccination gener-
ated superior T cell responses than i.n. nanodisc vaccination and
eliminated TC-1 tumors from the lungs, inner lip, and reproduc-
tive tract. Furthermore, we performed a head-to-head compari-
son study between a nanodisc vaccine and a Listeria-based live
vector vaccine, a representative cancer vaccine in the late stage of
clinical development.[6] While both vaccine platforms combined
with ICB achieved comparable levels of T cell responses and tu-
mor regression rates, nanodisc s.c. vaccination offers a conve-
nient off-the-shelf product and a safer alternative to intravenous
vaccination with live attenuated Listeria vaccines. Lastly, HLA-
A02 transgenic mice immunized with nanodiscs elicited strong
T cell responses against HLA-A02-restricted antigens, including
a neoantigen from a melanoma patient and M2 flu antigen, thus
demonstrating the versatility of the nanodisc platform for a wide
range of peptide antigens.
2. Results and Discussion
2.1. Subcutaneous Nanodisc Vaccination Induces Strong
E7-Specific CD8+ T Cell Responses
Recruitment of CD8+ T cells into the TME is critical for success-
ful cancer immunotherapy, especially for tumors located in mu-
cosal tissues characterized by a low frequency of T cells.[28,31] Pre-
viously, i.n. vaccination has been shown to promote T cell infiltra-
tion in mucosal tumors, such as lung tumors and head & neck
tumors by targeting lung-associated mediastinal LNs; however,
it remains unclear whether i.n. vaccination is effective against
distal mucosal tumors, such as intravaginal tumors.[28,30-33] Here,
we set out to examine whether potent systemic T cell responses
elicited by parenteral vaccination with a potent vaccine platform
can lead to T cell infiltration into local as well as disseminated
mucosal tumors (Figure 1).
Throughout our studies, we synthesized nanodiscs as de-
scribed previously[5,19,20] and observed efficient loading of
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Figure 2. Subcutaneous nanodisc vaccination induced effective cancer antigen-specific T cell response via efficient lymph node draining. A,B) C57BL/6
mice were vaccinated on days 0 and 14 with 20 𝜇g E7 peptide and 10 𝜇g CpG in the indicated formulations. Vaccines were given via either the sub-
cutaneous (s.c.) route at tail base or intranasal (i.n.) route. On day 21, the frequency of E7-specific CD8+ T cells among PBMCs was measured by the
tetramer staining assay. Shown are A) the representative flow cytometry scatter plots and B) the average values. C) Serial PET images of C57/BL mice at
various time points post-injection of 64Cu-NOTA-E7 or 64Cu-NOTA-nanodisc-E7. D,E) Time−radioactivity curves of Injection site, axillary LNs, inguinal
LNs, intestine, liver, blood, and muscle after s.c. injection. F) Biodistribution of 64Cu-NOTA-E7 and 64Cu-NOTA-nanodisc-E7 at 46 h post-injection. Data
are presented as mean ± s.e.m. from a representative experiment from 2 independent experiments (n = 4–5). *p < 0.05, **p < 0.01, ****p < 0.0001
analyzed by (B) one-way ANOVA or (F) two-way ANOVA, with Tukey’s HSD multiple comparison post hoc test.
peptide antigens and cholesterol-CpG (Table S1, Supporting
Information). We compared nanodisc vaccination given via
the s.c. or i.n. route of administration. C57BL/6 mice were
vaccinated either at the s.c. tail base area or both nostrils on
days 0 and 14 with nanodiscs containing 20 𝜇g E7 peptide and
10 𝜇g CpG. The control groups included the same doses of E7
peptide and CpG formulated in a soluble form or emulsified in
Montanide. On day 21, we examined the frequency of antigen-
specific CD8+ T cells among PBMCs with the tetramer staining
assay. Nanodisc vaccination induced ≈32% E7-specific CD8+ T
cells among PBMCs, representing a 29-fold increase compared
with the soluble vaccine or a 15-fold increase compared with
the Montanide control (Figure 2A,B). Interestingly, nanodiscs
administered via the i.n. route induced only ≈3.8% E7-specific
CD8+ T cells among PBMCs (Figure 2A,B). These results
indicated that nanodisc vaccination administered via the s.c.
route elicited more potent E7-specific CD8+ T cell responses in
the systemic compartment, compared with conventional soluble
peptide vaccines or intranasal nanodiscs vaccination.
We examined the biodistribution profiles of nanodiscs with
positron emission tomography (PET) imaging. Nanodisc vacci-
nation given via the s.c. route resulted in a significant amount of
64Cu-tagged E7 antigen accumulating in multiple draining LNs
(dLNs) even within 1 h of injection (Figure 2C,E). After 46 h, we
detected ≈20% injection dose per gram of tissue in proximal in-
guinal LNs as well as in distal axillary LNs (Figure 2E). On the
other hand, free E7 peptide administered s.c. resulted in rapid
systemic dissemination of antigen with minimal signal in dLNs
(≈4% and ≈11% ID per g for axillary and inguinal dLNs, respec-
tively) (Figure 2C,D). To validate the results, we isolated various
tissues at 46 h and quantified radioactivity of 64Cu with gamma
counter. Ex vivo measurement indicated that s.c. nanodisc vacci-
nation increased delivery of E7 antigen to axillary and inguinal
LNs by 12-fold and 2.3-fold, respectively, compared with free sol-
uble vaccination (Figure 2F). In contrast, i.n. vaccination resulted
in the accumulation of nanodiscs in the lungs, cervical LNs, and
GI tract (data not shown).
2.2. Therapeutic Vaccination against Lung Metastasis
Next, we examined whether strong systemic T cell responses
induced by s.c. nanodisc vaccination can inhibit tumor growth
in mucosal tissues. We first evaluated the therapeutic effect
of nanodiscs in a lung metastasis model. C57BL/6 mice were
administered intravenously with TC-1 tumor cells expressing
HPV16 E6/E7. Nontreated animals died within 25 days of tumor
inoculation due to tumor burden and difficulty in breathing
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Figure 3. Nanodisc vaccination in the TC-1 lung metastasis model. A–F) To establish a lung metastasis model, C57BL/6 mice were inoculated intra-
venously with 1 × 105 TC1-luc cells on day 0. On days 10 and 16, animals were vaccinated with 20 𝜇g E7 peptide and 10 𝜇g CpG formulated as a soluble
vaccine or sHDL vaccine. Vaccines were given via either s.c. at the tail base or intranasal (i.n.) route. A) Tumor burden was monitored over time using
in vivo whole animal imaging (IVIS). B) Animal survival was measured over 60 days. C–F) Three days after the second vaccination, the frequency of
E7-specific CD8a+ T cells was measured among C,D) PBMCs or E,F) lung tissues by the tetramer staining assay. Shown are C,E) the representative
flow cytometry scatter plots and D,F) the average values of E7-tetramer+ CD8𝛼+ T-cells. Data are presented as mean ± s.e.m. from a representative
experiment from 2 independent experiments (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 analyzed by (D,F) one-way ANOVA with
Tukey’s HSD multiple comparison post hoc test or by (B) log-rank (Mantel−Cox) test.
(Figure 3A,B). Subcutaneous vaccination with a soluble mixture
of 20 𝜇g E7 peptide and 10 𝜇g CpG had only a moderate effect,
with all animals succumbing to the tumor burdenwithin 30 days.
In stark contrast, s.c. vaccination with nanodiscs carrying the
same dose of E7 peptide and CpG (sHDL-E7/CpG) eliminated
lung metastases within 2 weeks after treatment without any sign
of tumor for 60 days (Figure 3A,B). Nanodisc vaccination via the
i.n. route also potently inhibited lung metastasis and prolonged
the animal survival (Figure 3A,B). T cell responses examined
on day 3 after the second vaccination revealed that s.c. nanodisc
vaccination induced ≈18% circulating E7-specific CD8+ T cells,
representing 5.7-fold stronger response than s.c. vaccination of
soluble vaccines (p < 0.0001, Figure 3C,D). Robust CD8+ T cell
response in circulation correlated with the high frequency of in-
tratumoral T cells, with nanodisc-immunized animals harboring
≈2.6-fold higher frequency of E7-specific CD8+ T cells within
the TME, compared with the soluble vaccine group (p < 0.0001,
Figure 3E,F). Notably, mice immunized with nanodisc via the
i.n. route generated weak E7-specific CD8+ T cell responses in
the systemic compartment, but they had a higher frequency of
E7-specific CD8+ T cells in the lung tissues, compared with s.c.
soluble vaccination (Figure 3C–F).
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Figure 4. The therapeutic effect of nanodisc vaccination in TC-1 head and neck cancer model. To establish a head and neck model, C57BL/6 mice were
inoculated with 50 000 TC1-luc cells in the inner lip on day 0. On days 6 and 12, animals were vaccinated with 20 𝜇g E7 peptide and 10 𝜇g CpG formulated
as a soluble vaccine or sHDL vaccine. The route of vaccination was either s.c. at the tail base or intranasal (i.n.) vaccination as indicated. A) Tumor burden
was monitored over time using in vivo whole animal imaging (IVIS). B) Animal survival was measured over 60 days. C–F) Three days after the second
vaccination, the frequency of E7-specific CD8𝛼+ T cells was measured among C,D) PBMCs or E,F) tumor tissues by the tetramer assay. Shown are C,E)
the representative flow cytometry scatter plots and D,F) the average values of E7-tetramer+ CD8𝛼+ T-cells. Data are presented as mean ± s.e.m. from
a representative experiment from 2 independent experiments (n = 5). *p < 0.05, ****p < 0.0001 analyzed by (D,F) one-way ANOVA with Tukey’s HSD
multiple comparison post hoc test or by (B) log-rank (Mantel−Cox) test.
2.3. Therapeutic Vaccination against Inner Lip Tumors
We evaluated the therapeutic effect of nanodisc vaccination
against sublingual inner lip tumor – a widely used orthotopic
model for HPV-associated head and neck cancer.[22,28,29] We es-
tablished the model by inoculating TC-1 tumor cells directly
in the inner lip of mice and initiated vaccination on day 6.
Nontreated animals died within 20 days of tumor inoculation.
Whereas s.c. vaccination with a soluble mixture of 20 𝜇g E7 pep-
tide and 10 𝜇g CpG led to ≈40% of animals eliminating tumor
cells, we observed 100% tumor eradication in animals vaccinated
s.c. with nanodiscs (Figure 4A,B). In contrast, i.n. nanodisc vac-
cination produced a moderate response with ≈60% survival rate.
Mice bearing TC-1 inner lip tumors generated ≈22% circulating
E7-specific CD8+ T cells after s.c. nanodisc vaccination, repre-
senting a 13-fold improvement over the soluble vaccine given
via the same route (p < 0.0001, Figure 4C,D). Strong systemic
T cell responses correlated with robust CD8+ T-cell infiltration
into inner lip tumors, with the s.c. nanodisc group having ≈3.6-
fold higher frequency of E7-specific CD8+ T cells in the TME,
compared with the s.c. soluble group (p < 0.0001, Figure 4E,F).
In contrast, i.n. vaccination with nanodiscs induced significantly
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Figure 5. The therapeutic effect of nanodisc vaccination in TC-1 cervical cancer model. To establish an HPV-associated cervical cancer model, C57BL/6
mice were inoculated with 4 × 104 TC1-luc cells in the vaginal tract on day 0. On days 6 and 12, animals were vaccinated with 20 𝜇g E7 peptide and
10 𝜇g CpG formulated as a soluble vaccine or sHDL vaccine. The route of vaccination was either s.c. at the tail base or intranasal (i.n.) vaccination as
indicated. A) Tumor burden was monitored over time using in vivo whole animal imaging (IVIS). B) Animal survival was measured over 60 days. C–F)
Three days after the second vaccination, the frequency of E7-specific CD8a+ T cells was measured among C,D) PBMCs or E,F) tumor tissues by the
tetramer staining assay. Shown are (C,E) the representative flow cytometry scatter plots and (D,F) the average values of E7-tetramer+ CD8a+ T-cells.
Data are presented as mean ± s.e.m. from a representative experiment from 2 independent experiments (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001 analyzed by (D,F) one-way ANOVA with Tukey’s HSD multiple comparison post hoc test or by (B) log-rank (Mantel−Cox) test.
lower frequency of E7-specific CD8+ T cells in circulation as well
as within the TME, comparable to the s.c. soluble vaccination
(Figure 4C–F).
2.4. Therapeutic Vaccination against Intravaginal Tumors
We also assessed nanodisc vaccination against intravaginal
TC-1 tumors, an aggressive model with clinical features of
HPV+ cervical cancer.[27] C57BL/6 mice were inoculated with
TC-1 cells into the vagina after diestrus synchronization as
previously reported[27,30,34] and vaccinated starting day 6 post
tumor inoculation. Non-treated animals died within 20 days,
while s.c. vaccination with a soluble mixture of E7 peptide and
CpG had a modest anti-tumor effect (Figure 5A,B). In stark
contrast, s.c. vaccination with nanodiscs significantly extended
the animal survival, with ≈40% of animals eliminating tumors
(Figure 5A,B). Notably, unlike in the case of lung and inner lip
tumormodels (Figures 3A,B and 4A,B), i.n. nanodisc vaccination
had a minimal impact on the animal survival (Figure 5A,B).
T cell analysis revealed that s.c. nanodisc vaccination in mice
bearing intravaginal TC-1 tumors elicited ≈23% circulating
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Figure 6. CD8+ T cell responses induced by nanodiscs and Listeria vaccine. A) C57BL/6 mice were vaccinated on days 0 and 30 with 107/100 𝜇L per
mouse Listeria-Gp33 (i.v. route) or sHDL nanodiscs carrying Gp33 and CpG (s.c. route). On days 7 and 35, splenocytes were re-stimulated with Gp33 for
intracellular cytokine staining (ICS) for IFN-𝛾 and TNF-𝛼. B) C57BL/6 mice were vaccinated on days 0 and 30 with 107/100 𝜇L per mouse Listeria-Adpgk
(i.v. route) or sHDL nanodiscs carrying Adpgk and CpG (s.c. route). Anti-PD-1 IgG was given i.p. on days 4 and 34. On days 7 and 35, splenocytes were
re-stimulated with Adpgk for ICS. Data are presented as mean ± s.e.m. from a representative experiment from 2 independent experiments (n = 7).
*p < 0.05, **p < 0.01, analyzed by one-way ANOVA with Tukey’s HSD multiple comparison post hoc test.
E7-specific CD8+ T cells, representing 11-fold and 13-fold
improvement over s.c. soluble vaccination and i.n. nanodisc
vaccination, respectively (p < 0.0001, Figure 5C,D). Similarly,
the s.c. nanodisc vaccine group had 2.3-fold and 2-fold higher
frequency of E7-specific CD8+ T cells in the intravaginal TME,
compared with s.c. soluble vaccination or i.n. nanodisc vaccina-
tion, respectively (p < 0.001, Figure 5E,F). Overall, these results
suggest that s.c. nanodisc vaccination elicits robust E7-specific
CD8+ T cell responses in circulation, leading to efficient T
cell infiltration into peripheral mucosal tumors, whereas i.n.
nanodisc vaccination was only effective against tumors proximal
to the site of vaccination (e.g., lungs and sublingual tissues).
2.5. Benchmarking Nanodiscs to Listeria-Based Vaccine
Given the strong therapeutic efficacy of nanodiscs, we sought to
directly compare nanodiscs to a leading T cell vaccine technology,
namely live attenuated Listeria vaccine, which has reached but ul-
timately failed in phase III trials.[6,10] First, we examined antigen-
specific T-cell responses in non-tumor bearingmice that received
either vaccine carrying a model antigen, Gp33 peptide, which is
an immunodominant epitope derived from lymphocytic chori-
omeningitis virus.[35] C57BL/6 mice were vaccinated s.c. at tail
base on days 0 and 30 with nanodiscs carrying Gp33 and CpG. In
parallel, mice were vaccinated on days 0 and 30 with Listeria vec-
tor encoding Gp33 administered via the i.v. route–the traditional
route employed in phase III trials.[6,10] On day 7 after priming vac-
cination, nanodiscs generated stronger Gp33-specific, polyfunc-
tional IFN-𝛾+TNF-𝛼+ CD8+ T cell responses than Listeria vac-
cination (Figure 6A). After the boost vaccination, both vaccine
groups achieved similar levels of Gp33-specific CD8+ T cell re-
sponses. Furthermore, we also compared nanodiscs to Listeria
vaccine using a neoantigen, Adpgk, derived from MC-38 colon
carcinoma model.[36] For this study, mice were also given anti-
PD-1 IgG or isotype IgG via intraperitoneal (i.p.) administration
on day 4 after each vaccination. While the prime vaccination re-
sulted in similar levels of neoantigen-specific CD8+ T cell re-
sponses between the nanodisc and Listeria groups, boost vacci-
nation with nanodiscs further improved Adpgk-specific CD8+ T
cell responses, compared with Listeria vaccination, regardless of
anti-PD-1 IgG co-treatment (Figure 6B).
To examine whether the strong systemic antigen-specific T
cell response could induce better T cell homing into tumor and
eradicate the tumor, we tested the therapeutic effect of nanodiscs
and Listeria vaccine in a subcutaneous MC38 tumor model. As
shown in Figure 7A, C57BL/6 mice were inoculated on day 0
with 5 × 105 MC-38 cells at s.c. flank. On day 10 and 17, MC-38
tumor-bearing mice were immunized with nanodiscs delivering
20 𝜇g Adpgk peptide and 15 𝜇g CpG or 1 × 107 CFU Listeria-
Adpgk-multiepitope. Nanodisc vaccines were administered at
s.c. tail base as above, whereas Listeria vaccines were given via i.v.
route. Anti-PD-1 IgG or isotype IgG was given i.p. on days 11, 14,
18, and 21. Nanodisc vaccination alone did not lead to tumor re-
gression, whereas Listeria vaccine alone eliminated tumors in 4
out of 10 animals (Figure 7B and Figure S1, Supporting Informa-
tion). In contrast, when combined with anti-PD-1 IgG, nanodisc
vaccines eradicated tumors in 4 out of 10 animals, which was
statistically comparable to Listeria vaccine plus anti-PD-1 IgG
therapy (Figure 7B). We also evaluated antigen-specific T cell
responses in circulation as well as in the TME. Listeria vaccine
alone group exhibited an increased trend of Adpgk-tetramer+,
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Figure 7. Comparison of therapeutic effect and T cell infiltration in TME after Nanodiscs and Listeria vaccine. A) C57BL/6 mice were inoculated at s.c.
flank with MC38 cancer cells on day 0. On days 10 and 17, animals were vaccinated with 107/100 𝜇L per mouse Listeria-Adpgk intravenously (i.v.) or
nanodisc-Adpgk/CpG (s.c.). Anti-PD-1 IgG was injected i.p. on days 11, 14, 18, and 21. For antitumor immune evaluation, the spleens were harvested
on day 28 and processed for peptide stimulation and intracellular cytokine staining (ICS). B) Tumor growth was monitored. C) Adpgk-specific CD8a+
T cells were quantified by the tetramer staining among PBMCs, spleen, and tumor tissues. D) PBMCs, spleen, and tumor tissues were isolated and
re-stimulated with Adpgk neoepitope, followed by intracellular cytokine staining. Data are presented as mean ± s.e.m. n = 10 for (B) and n = 4–7 for
(C,D).
IFN-𝛾+TNF-𝛼+ polyfunctional CD8+ T cells, compared with
nanodisc vaccine group (Figure 7C,D). However, nanodiscs
co-treated with anti-PD-1 IgG amplified antigen-specific T cell
responses in circulation and TME for the nanodisc group, reach-
ing comparable levels as in the Listeria vaccine + anti-PD-1 IgG
group (Figure 7C,D). Note that we administered live attenuated
Listeria vaccine via i.v. route since s.c. vaccination of Listeria
vectors has been reported to induce much weaker immune
response.[37] Overall, these studies showed that s.c. nanodisc
vaccination is a promising platform for cancer vaccination.
2.6. Nanodisc Vaccination with Human HLA-A02 Epitopes
Lastly, we examined the nanodisc platform for eliciting T
cells against a human neo-antigen derived from a HLA-A02
melanoma patient.[38] For the control group, HLA-A02 trans-
genic mice were vaccinated with 10 𝜇g per dose HLA-A02
neoantigen peptide and 2 𝜇g tetanus toxoid emulsified in Com-
plete Freund’s Adjuvant (CFA), which is a potent yet toxic adju-
vant system.[39,40] Nevertheless, HLA-A02 transgenic mice that
received prime-boost-boost immunizations with CFA-TT adju-
vant system generated only a basal level of IFN-𝛾+ T cell re-
sponse (Figure 8A,B). Strikingly, switching the last boost im-
munization with sHDL nanodiscs achieved >200-fold stronger
neoantigen-specific IFN-𝛾+ T cell responses (p < 0.001, Fig-
ure 8A,B). We also employed an HLA-A02-restricted influenza
peptide, GILGFVFTL (M158-66) as a positive control. After HLA-
A02 transgenicmice were prime-boost vaccinated with nanodiscs
carrying either HLA-A02-restricted melanoma neoantigen or flu
antigen, we observed robust IFN-𝛾+ CD8+ T cell responses
among PBMCs, as shown by intracellular cytokine staining (Fig-
ure 8C,E). Overall, these results suggest that the nanodisc plat-
form is compatible with other vaccine technologies in heterol-
ogous immunization regimens and generates robust T cell re-
sponses to a wide range of antigens, including HLA-restricted
antigens.
3. Conclusion
In this work, we examined antigen-specific T cell responses gen-
erated by nanodisc vaccination and compared the strength of
nanodiscs vaccine against other vaccine platforms. We chose
HPV16 E7 antigen for our initial studies since HPV16 E7 is
one of the most thoroughly studied antigens in the context of
HPV-associated cancer.[4,10,14] Among various therapeutic HPV
vaccines under development, TA-HPV and Lm-LLO-E7 target-
ing HPV16 E6/E7 are the leading vaccine candidates. TA-HPV
was first evaluated clinically in the 1990s. Three out of eight pa-
tients with late-stage cervical cancer generated antigen-specific T
cell responses against HPV, and two of them remained tumor-
free after 15 and 21 months of vaccination.[9] The subsequent
clinical studies showed that TA-HPV induced serological and
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Figure 8. A) HLA-A02 transgenic mice were vaccinated on days 0 and 14 with 10 𝜇g per dose of neoantigen peptide from a HLA-A02 melanoma patient
in Complete Freund’s Adjuvant (CFA) containing 2 𝜇g per dose of tetanus toxoid. On day 28, the animals were boosted with either the same CFA +TT
formulation or nanodiscs containing 15𝜇g per dose of CpG. B)On day 35, antigen-specific T cell responses were evaluated by ELISPOT after restimulating
splenocytes with 0.1, 1, or 10 𝜇g mL−1 of the antigen peptide. C) HLA-A02 transgenic mice were vaccinated on days 0 and 21 with nanodiscs containing
15 𝜇g per dose of CpG and either neoantigen peptide from an HLA-A02 melanoma patient (Mel-Ag) or HLA-A02-restricted flu antigen peptide, M158-66.
D,E) On day 28, PBMCswere analyzed for antigen-specific, IFN-𝛾+ T-cell responses by intracellular cytokine staining after ex vivo restimulation with 10 𝜇g
mL−1 of each peptide. Data are presented as mean ± s.e.m. from a representative experiment from 2 independent experiments (n = 3). ****p < 0.0001
analyzed by (B) two-way ANOVA with Tukey’s HSD multiple comparison post hoc test.
T cell responses, alleviating HPV-associated lesions.[14,15] Lm-
LLO-E7, which is based on Listeria vector expressing E7 anti-
gen fused to a part of virulence factor, listeriolysin O, has
been evaluated in phase I-III studies.[11] The first study, pub-
lished in 2009, showed that i.v. administration of Lm-LLO-E7
induced E7-specific T cell responses, but 40% patients experi-
enced grade 3 side effects.[6] To address the safety issues and
regulatory challenges associated with live vectors, peptide-based
subunit vaccines with HPV16 E6/E7 antigens have been stud-
ied extensively.[7,41,42] However, peptide-based subunit vaccines
generally suffer from limited anti-tumor efficacy due to ineffi-
cient antigen delivery to lymphoid tissues and the lack of ap-
propriate innate immune stimulation.[4,12] In our previous work,
we have shown that the nanodisc vaccine technology adminis-
tered s.c. can efficiently drain to LNs and generate potent antigen-
specific T cell responses.[5,19,20,43] In this work, we have uti-
lized the nanodisc platform for therapeutic vaccination targeted
against HPV16 E7 and shown elicitation of robust E7-specific
CD8+ T cells, leading to the elimination of TC-1 tumors inoc-
ulated in various mucosal tissues, including intravaginal TC-1
model known for low T cell infiltration and aggressive features
of HPV+ cervical cancer.[27,30,34] Importantly, in our head-to-head
comparison studies, nanodisc vaccination induced comparable
levels of antigen-specific CD8+ T cell responses as Listeria vec-
tors (Figures 6 and 7) but without any overt sign of toxicity or
anti-vector immunity associated with live vector vaccines.
Efficient infiltration of T cells in solid cancer is a major
challenge for therapeutic vaccines, especially for HPV-associated
tumors in mucosal sites.[44-46] Previous studies have reported
that i.n. vaccination targets DCs in proximal draining LNs and
promotes T cell infiltration in mucosal tumors, including lungs
and head and neck cancer.[28,31] However, it remains unclear
whether i.n. vaccination can also promote T cell infiltration
into distant mucosal tumors, such as in the reproductive tract,
characterized by a low frequency of T cells and unresponsiveness
to conventional therapies.[27,32] Here, we have demonstrated that
s.c. vaccination with nanodiscs induced up to ≈32% E7-specific
CD8+T cells in circulation, leading to efficient intratumoral infil-
tration of T cells against mucosal tumors in the lungs, inner lip,
and intravaginal tissues. In contrast, i.n. nanodisc vaccination
failed to induce T cell infiltration into distal mucosal sites (i.e.,
intravaginal tissues) (Figure 5), whereas we observed modest T
cell infiltration intomucosal tissues proximal to the site of immu-
nization (e.g., the lungs and inner lip) (Figures 3 and 4). While
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the exact mechanism of action is beyond the scope of this paper,
we speculate that s.c. nanodisc vaccination allows for efficient dis-
semination of nanodiscs from the injection site to multiple LNs,
including inguinal and axillary LNs (Figure 2), leading to a high
frequency of antigen-specific CD8+ T cells in the circulation and
subsequent infiltration of CD8+ T cells into peripheral mucosal
tumors that release cytokine/chemokine signals and/or antigens.
To demonstrate the broad applicability of nanodisc vaccine,
we evaluated whether the nanodisc platform can elicit T cell re-
sponses against HLA-restricted antigens, including a neoanti-
gen from HLA-A02 melanoma patient as well as a widely used
influenza epitope M158-66. Interestingly, nanodisc immuniza-
tion rescued low level of T cell responses observed in HLA-
A02 transgenic mice after CFA plus tetanus toxoid vaccination
and elicited significantly amplified antigen-specific T cell re-
sponses against HLA-A02-restricted neoantigen (Figure 8A,B).
We have also demonstrated induction of robust CD8+ T cell re-
sponses against M158-66 epitope. These results show that nan-
odiscs are broadly applicable with a wide range of antigens, in-
cluding neoantigens, shared tumor antigens, and viral antigens,
and are compatible with other vaccine platforms in the context of
heterologous vaccination. Overall, nanodiscs offer a versatile and
promising vaccine platform for eliciting robust T cell immunity





pyridyldithio)propionate] (DOPE-PDP) were purchased from Avanti
Polar Lipids (Alabaster, AL). S-2-(4-Isothiocyanatobenzyl)-1,4,7-
triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was purchased
from Macrocyclics, Inc. (Dallas, TX). SEPPIC INC MONTANIDE (Cat-
alog# NC0962946) was purchased from Fisher Scientific. E7 peptide
(GQAEPDRAHYNIVTFCCKCD), HLA-A02-restricted flu antigen peptide
(CSSGILGFVFTL) and HLA-A02-restricted melanoma patient peptide
(CSS-GIPENSFNV) were synthesized by AnaSpec (Fremont, CA). Gp33
peptide (CSSKAVYNFATM) and Adpgk peptide (CSSASMTNMELM) were
respectively synthesized by Genemed Synthesis (San Antonio, TX) and
RS Synthesis (Louisville, KY). The oligodeoxynucleotide TLR9 ligand CpG
1826 (5’-tccatgacgttcctgacgtt-3’, lower case letters represent phospho-
rothioate backbone), and CpG 1826 modified with cholesterol (Cho-CpG)
were synthesized by Integrated DNA Technologies (Coralville, IA). Anti-
mouse CD16/32 was from eBioscience (San Diego, CA). Anti-mouse
CD8𝛼-APC (Catalog# 553 035) were from BD Biosciences (San Jose,
CA). Anti-CD4-FITC (Catalog# 100 406), anti-CD8-PerCPCy5.5 (Catalog#
100 734), anti-IFN𝛾-APC (Catalog# 505 810), anti-TNF𝛼-PE-Cy7 (Cata-
log#506 324), anti-IL-2-BV421 (Catalog#503 825), and anti-CD40L-PE
(Catalog# 106 506) were from BioLegend. Tetramer H-2Db-RAHYNIVTF-
BV421 was kindly provided by the NIH Tetramer Core Facility (Atlanta,
GA).
Cell Culture: TC-1 cells expressing luciferase (TC-1-luc) were kindly
provided by Dr. T. C. Wu from Johns Hopkins University (Baltimore, MD).
The cells were cultured in RPMI 1640 medium supplemented with 10%
FBS, 100 U mL−1 penicillin and 100 𝜇g mL−1 streptomycin, 2 × 10−3 m
glutamine, 1 × 10−3 m sodium pyruvate, non-essential amino acids, and
400 𝜇g mL−1 G418. MC38 cells were cultured in Dulbecco’s Modified Ea-
gle Media (DMEM) supplemented with 10% v/v heat-inactivated FCS at
Bristol Myers Squibb.
Preparation of Vaccine Nanodiscs: Vaccine nanodiscs were prepared
following the previous reports.[5] Briefly, DMPC and 22A in the weight ratio
of 2:1 were dissolved in acetic acid, followed by lyophilization and hydra-
tion with PBS to form nanodiscs. Each antigen peptide was reacted with
DOPE-PDP at a 1.5:1 molar ratio, and the resulting lipid-peptide conju-
gates were dissolved in DMSO and incubated with pre-formed nanodiscs
at room temperature for 30 min. Unreacted antigen peptides were re-
moved by ultrafiltration. Cholesterol modified CpG was incubated with
nanodiscs for 30min. Table S1 (Supporting Information) shows the conju-
gation efficiency of tumor antigen peptides as determined by LC-MS, and
the loading efficiency of CpG as measured by gel permeation chromatog-
raphy.
Tumor Models and Therapy: Mice were cared for following the federal,
state, and local guidelines. All work performed on animals was in accor-
dance with and approved by the University Committee on Use and Care
of Animals (UCUCA) at the University of Michigan, Ann Arbor, and Bris-
tol Myers Squibb. Female C57BL/6 (5–6 weeks) were purchased from En-
vigo or Jackson Laboratory (USA). For the lungmetastasismodel, C57BL/6
mice were intravenously injected with 1 × 105 TC-1-luc cells on day 0. For
the inner lip tumors,[29] C57BL/6 mice were injected with 50 000 TC-1-
luc cells in the inner lip on day 0. For the HPV-associated cervical can-
cer model,[27,30,34] female mice received s.c. injection of medroxyproges-
terone (3mg permouse) for diestrus synchronization, and after 4 days, the
animals were inoculated with 40 000 TC-1-luc cells by intravaginal admin-
istration. For each model, animals were vaccinated on indicated days with
20 𝜇g E7 and 10 𝜇g CpG through tail base s.c. vaccination or intranasal
vaccination. Bioluminescence from tumor cells was visualized using IVIS
after intraperitoneal (i.p.) injection of luciferin.
For comparison of vaccine nanodiscs and Listeria vector vaccine,
C57BL/6 mice were injected on days 0 and 30 with nanodiscs at s.c.
tail base or 107/100 𝜇L per mouse Listeria-Gp33/Adpgk intravenously
(i.v.). Listeria was cultured in sterile Brain Heart Infusion Broth, Modified
(Teknova Inc., Hollister, CA) overnight to achieve stationary phase culture
of 109 CFU mL−1 which was further diluted with Hank’s Balanced Salt
solution (HBSS) to make 108 CFU mL−1 for vaccination. On Day 7 post
priming and day 5 post boost, spleen was harvested and processed for
antigen stimulation and intracellular cytokine staining (ICS). For the ther-
apeutic studies in the MC38 model, C57BL/6 mice were subcutaneously
injected with 0.5 million MC38 cells on day 0. On days 10 and 17, animals
were vaccinated with nanodiscs at s.c. tail base or i.v. with 107/100 𝜇L per
mouse Listeria vaccine. A subset of animals received 100 𝜇g anti-PD-1 i.p.
on days 11, 14, 18, and 21.
For evaluation of immune responses of HLA-A02-restricted peptides,
HLA-A02 transgenic mice (Jackson Laboratory, Bar Harbor, ME) were im-
munized on indicated days with vaccine formulations. Mice were vacci-
nated with 10 𝜇g per dose of neoantigen peptide (SILMHGLVSL) from
a HLA-A02 melanoma patient in the form of either CFA containing 2 𝜇g
per dose of tetanus toxoid or nanodiscs containing 15 𝜇g per dose of
CpG. For a positive control group, HLA-A02 mice were immunized with
nanodiscs delivering 10 𝜇g per dose of A02-restricted influenza peptide,
M158–66 GILGFVFTL and 15 𝜇g per dose of CpG.
Copper-64 Labeling of Nanodiscs and PET Imaging: Copper-64 (64Cu)
was produced with an onsite cyclotron (GE PETtrace). 64CuCl2 (74 MBq)
was diluted in 0.3 mL of 0.1 m sodium acetate buffer (pH 5.0) and mixed
with 0.5 mg of nanodisc. The reaction was conducted at 37 °C for 30 min
with constant shaking. Then 5 𝜇L 0.1 m EDTA (ethylenediaminetetraacetic
acid) was added into the solution and shaken for 5 min to remove non-
specifically bound 64Cu. The resulting 64Cu-NOTA–nanodisc was purified
by PD-10 size exclusion column chromatography using PBS. The radioac-
tive fractions were collected for further in vivo studies. C57BL/6 mice
were administered with 5–8 MBq of 64Cu-NOTA–nanodisc via s.c. or in-
tranasal route, and PET imaging was performed over time using a mi-
croPET/microCT Inveon rodent model scanner (Siemens Medical Solu-
tions USA, Inc.). Quantitative PET data for the major organs were pre-
sented as the percentage injected dose per gram of tissue (%ID g−1). To
validate these results, blood and major organs/tissues were collected and
weighed at 24 h post-injection, and the samples were measured for ra-
dioactivity using a gamma counter (PerkinElmer).
Examination of T Cell Responses: The frequency of tumor antigen-
specific CD8𝛼+ T cells was analyzed using the tetramer staining assay
as described previously.[5] Blood was collected from each mouse by
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submandibular bleeding, and red blood cells were lysed using
Ammonium-Chloride-Potassium (ACK) lysis buffer. Tumor tissues
harvested on indicated time points were cut into small pieces of 2 to
4 mm, and cells were dissociated in digestion buffer [collagenase type IV
(1 mg mL−1) and deoxyribonuclease I (100 U mL−1) in serum-free RPMI]
for 30 min at 37 °C with gentle shaking. Cell suspension was passed
through a 70 𝜇m nylon strainer and washed with FACS buffer (1% BSA in
PBS). Cells were then incubated with CD16/32 for 10 min, incubated with
peptide-MHC tetramer (H-2Db-RAHYNIVTF-BV421) for 30 min at room
temperature, and stained with antibodies against CD8a (53-6.7) on ice
for 20 min. Cells were washed twice with FACS buffer and resuspended
in 7AAD solution (0.5 𝜇g mL−1) for analysis by flow cytometry (Cyan 5,
Beckman Coulter).
For intracellular cytokine staining (ICS) assay, 100–150 𝜇L peripheral
blood collected from vaccinated mice was lysed with ACK lysis buffer,
washed with PBS, and plated at ≈10 million cells per mL in 50 𝜇L T cell
media (RPMI 1640 supplemented with 10% FBS, 2 × 10−3 m L-glutamine,
55 × 10−6 m 𝛽-mercaptoethanol, 1 × 10−3 m pyruvate, 100 U mL−1 peni-
cillin, 100 𝜇g mL−1 streptomycin, HEPES, and non-essential amino acids)
in 96-well U bottom plates. Cells were pulsed with 10 𝜇g mL−1 antigen
peptides for 6 h, with brefeldin A (BD Biosciences) added during the last
4 h of incubation. Cells were then washed twice with ice-cold FACS buffer,
followed by incubation with anti-CD16/32 for 10 min and anti-CD8𝛼 for
20 min on ice. Cells were then fix/permeabilized for 20 min on ice and
then stained with anti-IFN-𝛾 or anti-TNF𝛼 for 30 min on ice. After exten-
sive washing, cells were analyzed by flow cytometry.
For ELISPOT assays, spleens from immunized mice were harvested,
processed into single cell suspensions for each mouse, and seeded in
96-well PVDF plates (EMD Millipore) pre-incubated overnight with IFN-
𝛾 coating Ab (R&D Systems). Splenocytes were co-incubated with antigen
peptides (2𝜇gmL−1) or controls for 24 h. Assays were completed using se-
quential incubations with biotinylated-secondary Ab, streptavidin-alkaline
phosphatase (Sigma Chemical), and NBT/BCIP substrate (Surmodics).
Spots developed were analyzed using an AID iSpot Reader (Autoimmun
Diagnostika GmbH, Germany).
Statistical Analysis: For animal studies, mice were randomized to
match the similar average tumor burden before the initiation of any treat-
ments. All procedures were performed in a non-blinded fashion. Statistical
analysis was performed with Prism 6.0 software (GraphPad Software) by
one-way or two ANOVA with Tukey’s HSD multiple comparison post hoc
test. Statistical significance for the survival curve was calculated by the
Mantel-Cox log-rank test. Statistical significance is indicated as *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001. Data were approximately
normally distributed, and variance was similar between the groups. Data
are presented as mean ± s.e.m. and sample sizes are reported in each
figure legend.
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